reports
Palo Alto Networks Inc: 1 director
A director at Palo Alto Networks Inc sold 36,000 shares at 288.245USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
Andrew Briggs Appointed Chairman of Farmers & Merchants Bancorp, Inc. ...
Andrew Briggs Appointed Chairman of Farmers & Merchants Bancorp, Inc. and F&M Bank ARCHBOLD, Ohio, May 03, 2024 (GLOBE NEWSWIRE) -- F&M Bank (“F&M”), an Archbold, Ohio-based bank owned by Farmers & Merchants Bancorp, Inc. (Nasdaq: FMAO) announced the appointment of Andrew Briggs as Chairman of the Board of both the Company and the Bank. As part of F&M’s comprehensive succession plan, current Board Chairman Jack Johnson will retire later this month after reaching the maximum age requirement as set forth in F&M’s bylaws. Kevin Sauder, President and CEO of Sauder Woodworking Company, will co...
Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to D...
Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host a conference call and live webcast to discuss the Company’s first quarter 2024 financial results and provide a business update at 8:30 a.m. ET on Tuesday, May 14, 2024. Ocugen will issue a pre-market e...
Eastman Kodak Company First – Quarter 2024 Earnings Conference Call
Eastman Kodak Company First – Quarter 2024 Earnings Conference Call ROCHESTER, N.Y., May 02, 2024 (GLOBE NEWSWIRE) -- Kodak will host the First-Quarter 2024 Earnings call on Thursday, May 9th 2024, at 5:00 pm ET. Executive Chairman and Chief Executive Officer James Continenza and Chief Financial Officer David Bullwinkle will host a conference call with financial analysts and investors to discuss the financial results. EVENT DETAILS Title: Eastman Kodak Q1 2024 Earnings Conference Call Start Date: 05/09/2024 Start Time: 5:00 PM EST AUDIO CONFERENCE DETAILS Aud...
Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina Wor...
Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress MALVERN, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Arun Upadhyay, PhD, Chief Scientific Officer, Head of Research & Development, Ocugen will speak at the Retina World Congress (RWC) being held May 9-12, 2024 in Ft. Lauderdale, FL. “This is a terrific opportunity to share the most recent developments in modifier gene ...
Farmers & Merchants Bancorp, Inc. Reports 2024 First-Quarter Financial...
Farmers & Merchants Bancorp, Inc. Reports 2024 First-Quarter Financial Results ARCHBOLD, Ohio, May 01, 2024 (GLOBE NEWSWIRE) -- Farmers & Merchants Bancorp, Inc. (Nasdaq: FMAO) today reported financial results for the 2024 first quarter ended March 31, 2024. 2024 First Quarter Financial and Operating Highlights (on a year-over-year basis unless noted): 84 consecutive quarters of profitabilityNet income was $5.4 million, or $0.39 per basic and diluted shareNet interest income after provision for credit losses increased 6.2% from December 31, 2023, primarily due to a stabilizing net i...
Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentat...
Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024 MALVERN, Pa., April 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Benjamin Bakall, MD, PhD, Director of Clinical Research at Associated Retina Consultants and Clinical Assistant Professor at the University of Arizona, College of Medicine—Phoenix will present data from the OCU400 Phas...
Donnelley Financial Solutions Inc: 1 director
A director at Donnelley Financial Solutions Inc sold 5,698 shares at 66.024USD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last ...
UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Assoc...
UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa (Phase 3 LiMeliGhT clinical trial), OCU410 for the treatment of geographic ...
Ocugen to Present on Modifier Gene Therapy Platform at Association for...
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa (Phase 3 LiMeliGhT clinical trial), OCU410 for the treatment of geographic atrophy (P...
Mark Hutchinson Joins F&M Bank as Treasurer
Mark Hutchinson Joins F&M Bank as Treasurer ARCHBOLD, Ohio, April 24, 2024 (GLOBE NEWSWIRE) -- F&M Bank (“F&M”), an Archbold, Ohio-based bank owned by Farmers & Merchants Bancorp, Inc. (Nasdaq: FMAO) announced that Mark Hutchinson has joined F&M as Treasurer. In this new position, Hutchinson will oversee certain financial operations including budgeting, planning, investing and other financial matters for the Bank. Hutchinson will report to the Company’s Chief Financial Officer. He has 22 years of experience working for 2 financial institutions in the areas of treasury, finance, and accou...
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy...
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy MALVERN, Pa., April 19, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete in the second cohort of its Phase 1/2 ArMaDa clinical trial for OCU410 (AAV-hRORA)—a modifier gene therapy candidate being developed for geographic atrophy (GA), an advanced...
- Wedbush Research
- Daniel Ives
- John Katsingris
- Sam Brandeis
- Scott Devitt
- Steven Wahrhaftig
- Taz Koujalgi
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual ...
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets MALVERN, Pa., April 12, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder will participate in a fireside chat during the Emerging Growth Virtual Healthcare Equity Conference, presented by Noble Capital Markets, taking place from A...
- Wedbush Research
KMX CARMAX INC.
TSLA TESLA INC
PANW PALO ALTO NETWORKS INC.
NVDA NVIDIA CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
CYBR CYBERARK SOFTWARE LTD.
CRM SALESFORCE.COM INC.
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
NFLX NETFLIX INC.
ROKU ROKU INC. CLASS A
MDB MONGODB INC. CLASS A
AMZN AMAZON.COM INC.
MSFT MICROSOFT CORPORATION
ZS ZSCALER INC.
TENB TENABLE HOLDINGS
ESTC ELASTIC N.V.
PINS PINTEREST INC. CLASS A
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
PLTR PALANTIR TECHNOLOGIES
VRDN VIRIDIAN THERAPEUTICS INC
SNOW SNOWFLAKE INC. CLASS A
- Daniel Ives
- John Katsingris
- Sam Brandeis
- Scott Devitt
- Steven Wahrhaftig
- Taz Koujalgi
NVDA NVIDIA CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
CYBR CYBERARK SOFTWARE LTD.
CRM SALESFORCE.COM INC.
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
MDB MONGODB INC. CLASS A
AMZN AMAZON.COM INC.
MSFT MICROSOFT CORPORATION
ZS ZSCALER INC.
TENB TENABLE HOLDINGS
ESTC ELASTIC N.V.
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
PLTR PALANTIR TECHNOLOGIES
SNOW SNOWFLAKE INC. CLASS A
Ocugen, Inc. Announces Positive Scientific Advice from the European Me...
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication MALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) reviewed the study design, endpoints and planned stati...
- Wedbush Research
W WAYFAIR INC.
2454 MEDIATEK INC.
MTB M&T BANK CORPORATION
STZ CONSTELLATION BRANDS INC. CLASS A
PHM PULTEGROUP INC.
INFY INFOSYS LIMITED
DPZ DOMINO'S PIZZA INC.
ACN ACCENTURE PLC CLASS A
XNCR XENCOR INC.
W9N WNS (HOLDINGS) LIMITED SPONSORED ADR
WDC WESTERN DIGITAL CORPORATION
TXRH TEXAS ROADHOUSE INC.
TSLA TESLA INC
TPH TRI POINTE HOMES INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
QCOM QUALCOMM INC
PSTG PURE STORAGE INC. CLASS A
PEGA PEGASYSTEMS INC.
PANW PALO ALTO NETWORKS INC.
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
MTH MERITAGE HOMES CORPORATION
MGPI MGP INGREDIENTS INC.
LGIH LGI HOMES INC.
INTC INTEL CORPORATION
IMAX IMAX CORPORATION
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
35G GENPACT LIMITED
FTNT FORTINET INC.
FHN FIRST HORIZON CORPORATION
EXLS EXLSERVICE HOLDINGS INC.
ETSY ETSY INC.
EPAM EPAM SYSTEMS INC.
DECK DECKERS OUTDOOR CORPORATION
CYBR CYBERARK SOFTWARE LTD.
CTSH COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION CLASS A
CMRX CHIMERIX INC
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
CCS CENTURY COMMUNITIES INC.
CAKE CHEESECAKE FACTORY INCORPORATED
BZH BEAZER HOMES USA INC.
AXTI AXT INC.
NFLX NETFLIX INC.
WD WALKER & DUNLOP INC.
WIPRO WIPRO LIMITED
DHI D.R. HORTON INC.
BJRI BJ'S RESTAURANTS INC.
GRBK GREEN BRICK PARTNERS
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
BLDR BUILDERS FIRSTSOURCE INC.
DRI DARDEN RESTAURANTS INC.
GLOB GLOBANT SA
TMHC TAYLOR MORRISON HOME CORPORATION
MHO M/I HOMES INC.
FCNCA FIRST CITIZENS BANCSHARES INC. CLASS A
OKTA OKTA INC. CLASS A
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
RCUS ARCUS BIOSCIENCES
AVGO BROADCOM INC.
ZS ZSCALER INC.
TENB TENABLE HOLDINGS
LEGH LEGACY HOUSING CORP
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
CHWY CHEWY INC. CLASS A
SWTX SPRINGWORKS THERAPEUTICS
SMCI SUPER MICRO COMPUTER
ORIC INC.
COGT ORIC PHARMACEUTICALS
UFPI COGENT BIOSCIENCES INC
LSEA UFP INDUSTRIES INC.
DFH LANDSEA HOMES CORP (A)
IMNM DREAM FINDERS HOMES
FHTX IMMUNOME
TNGX FOGHORN THERAPEUTICS
MRVL TANGO THERAPEUTICS
STX INC
IKNA MARVELL TECHNOLOGY INC
TSVT SEAGATE TECHNOLOGY HLDGS PLC
HOWL IKENA ONCOLOGY INC
GFS 2SEVENTY BIO INC
CMPX WEREWOLF THERAPEUTICS INC
S GLOBALFOUNDRIES INC
FUSN COMPASS THERAPEUTICS
BROS SENTINELONE INC
SDHC FUSION PHARMACEUTICALS INC
DUTCH BROS INC
SMITH DOUGLAS HOMES CORP
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.